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Purpose
Active cellular therapy (ACT) using ex-vivo expanded T
cells from patients with cancer, obtained by apheresis,
can represent a viable source for anti-cancer directed
cellular therapy. We established a T cell expansion pro-
tocol using 2 rounds of re-stimulation with TAA pep-
tides along with IL-2, IL-15 and IL-21. In order to
gauge the ex-vivo cellular reactivity as well as the poten-
tial to successful expand antigen-specific T cells from
patients with pancreatic cancer, we established a screen-
ing assay using whole-heparin blood, to gauge for TAA
reactivity (NY-ESO-1, survivin and mesothelin) and con-
trol antigens (EBNA-1, EBNA-3, CMVpp65).
Methods
Fresh blood samples were obtained from 24 patients
with pancreatic cancer and from 6 individuals with
pre-malignant lesions and tested for anti-TAA reactivity.
T cells were expanded without cytokines, with IL-2 and
IL-7, or with IL-2, IL-15 and IL-21 and tested for CD4/
8 expansion by flow cytometry and for IFN-gamma pro-
duction. PBMCs were expanded by cytokines and TAA
peptides. CD3, CD4, CD8, CD45RA and CCR7 was
determined by flow cytometry and TAA-reactive T cells
were identified by ICS (IL-2, TNF, IFN and IL-17).
Results
We could detect IFN-gamma responses in 90% (27 in 30)
in blood samples for mesothelin, 55,3% (16 in 30) for sur-
vivin and 43,3% (13 in 30) for NY-ESO-1. Cellular
responses could be augmented by adding cytokines, i.e.
IL-2 and IL-7 could favored CD4+ T cell proliferation,
IL-2, IL-15 and IL-21 favored CD8+ T cell proliferation.
TAAs-reactive T cells could be successfully expanded in
vitro and exhibited TAA-specific production of IFN-
gamma and TNFalpha and a CD8+CD45RA-CCR7+
phenotype.
Conclusion
A TAA-specific WBA (whole blood assay) can be used to
gauge the potential for expansion of TAA-reactive T cells
in peripheral blood from patients with pancreatic cancer.
TAA-reactive T cells can be successfully expanded in IL-2,
IL-15 and IL-21 and could represent a viable source for
the cellular therapy of patients with pancreatic cancer.
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